---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-005043"
form_type: "8-K"
ticker: "IMMX"
cik: "0001873835"
company_name: "Immix Biopharma, Inc."
filed_at: "2024-02-06T23:59:59+00:00"
generated_at: "2026-06-06T08:32:03.269062+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Immix Biopharma prices $15M public offering of 5.5M shares at $2.71/share

## Summary
- Offering of 5,535,055 shares at $2.71 per share; gross proceeds ~$15M before expenses.
- Underwriter granted 30-day over-allotment option for up to 783,970 additional shares.
- Net proceeds to fund NXC-201 clinical trials, working capital, and general corporate purposes.
- Closing expected February 8, 2024; subject to customary conditions.
- Directors and officers subject to 90-day lock-up expiring May 8, 2024.

## SEC filing metadata
- accession: 0001493152-24-005043
- form_type: 8-K
- ticker: IMMX
- cik: 0001873835
- company_name: Immix Biopharma, Inc.
- filed_at: 2024-02-06T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1873835/000149315224005043/0001493152-24-005043-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1873835/000149315224005043/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-005043
- JSON: https://secwatch.observer/filing/0001493152-24-005043.json
- Plain text: https://secwatch.observer/filing/0001493152-24-005043.txt

## Key facts
- Material Agreements
  Immix Biopharma, Inc. entered into Underwriting Agreement with Titan Partners Group LLC, a division of American Capital Partners, LLC valued at $15 million (effective 2024-02-05).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: Titan Partners Group LLC, a division of American Capital Partners, LLC
  - Value: $15 million
  - Effective: 2024-02-05
  source text: On February 5, 2024, Immix Biopharma, Inc. (the “Company”) entered into an Underwriting Agreement (the “Agreement”) with Titan Partners Group LLC, a division of American Capital Partners, LLC (the “Underwriter”), relating to an underwritten offering (the “Offering”) of 5,535,055 shares (“Shares”) of common stock of the Company (“Common Stock”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1873835/000149315224005043/0001493152-24-005043-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.